Economic impact of opioid abuse, dependence, and misuse

American Journal of Pharmacy Benefits

Volumn 3, Issue 3, 2011, Pages

  White, Alan G ^a   Birnbaum, Howard G ^a   Schiller, Matt ^a   Waldman, Tracy ^a   Cleveland, Jody M ^b   Roland, Carl L ^b  

^a ANALYSIS GROUP   (United States)

^b King Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

ADOLESCENT; ADULT; ARTICLE; CAREGIVER BURDEN; CHILD; CHRONIC PAIN; COMORBIDITY; CONTROLLED STUDY; DRUG ABUSE; DRUG MISUSE; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DISEASE; OPIATE ADDICTION; PREVALENCE; PUBLIC HEALTH PROBLEM; SCHOOL CHILD;

EID: 79954614467     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. The National Center on Addiction and Substance Abuse at Columbia University. Under the counter: the diversion and abuse of controlled prescription drugs in the US. www.casacolumbia.org/download.aspx?path=/UploadedFiles/...pdf. Published July 2005. Accessed July 7, 2009.
2. Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221-227.
3. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2002 National Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2003. NSDUH series H-22. DHHS publication SMA 03-3836.
4. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2010. NSDUH Series H-38A, DHHS publication SMA 10-4856.
5. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). Quick statistics from the Drug and Alcohol Services Information System. Summary tables. http://wwwdasis.samhsa.gov/webt/tedsweb/tab_year.choose_year_web_table?t_state=US. Accessed October 18, 2010.
6. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief. 2009;(22):1-8.
7. The Associated Press. Drug deaths outpace auto fatalities in more states. http://www.msnbc.msn.com/id/33091645/. Published September 30, 2009. Accessed October 20, 2010.
8. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA. 2007;297(3):249-251.
9. Birnbaum H, White A, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001. Clin J Pain. 2006;22(8):667-676.
10. White A, Birnbaum H, Mareva M, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11(6):469-479.
11. McAdam-Marx C, Roland CL, Cleveland J, Oderda GM. Costs of opioid abuse and misuse determined from a Medicaid database. J Pain Palliat Care Pharmacother. 2010;24(1):5-18.
12. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm. 2009;15(7):556-562.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
14. Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46(10):1075-1079.
15. Bureau of Labor Statistics. Consumer Price Index for Medical Care. http://www.bls.gov/cpi/. Accessed October 19, 2010.
16. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Results From the 2007 National Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration. Office of Applied Studies; 2008. NSDUH series H-34. DHHS publication SMA 08-4343.
17. US Census Bureau, Population Division. Table 1: Annual estimates of the resident population for the United States, Regions, States, and Puerto Rico: April 1, 2000 to July 1, 2008 (NST-EST2008-01). http://www.census.gov/popest/states/NST-ann-est.html. Accessed September 8, 2009.
18. Cohen MJ, Jasser S, Herron PD, Margolis CG. Ethical perspectives: opioid treatment of chronic pain in the context of addiction. Clin J Pain. 2002;18(4) (suppl):S99-S107.
19. Ruetsch C. Empirical view of opioid dependence. J Manag Care Pharm. 2010; 16(1) (suppl B):S9-S13.
20. McCabe SE, Boyd CJ. Sources of prescription drugs for illicit use. Addict Behav. 2005;30(7):1342-1350.
21. El-Aneed A, Alaghehbandan R, Gladney N, Collins K, MacDonald D, Fischer B. Prescription drug abuse and methods of diversion: the potential role of a pharmacy network. J Subst Abuse. 2009;14(2):75-83.
22. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107-112.
23. Food and Drug Administration. NDA Approval Letter for Embeda. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022321s000ltr.pdf. Published August 13, 2009. Accessed August 31, 2009.
24. White AG, Birnbaum HG, Rothman DB, Katz N. Development of a budgetimpact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy. 2009;7(1):61-70.
25. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11-18.
26. Inciardi JA, Surratt HL, Cicero TJ, Beard RA. Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment. Pain Med. 2009;10(3):537-548.
27. American Society of Interventional Pain Physicians. NASPER: National All Schedules Prescription Electronic Reporting Act. http://www.nasper.org/bill.html. Published 2007. Accessed August 31, 2009.
28. Fishman SM. Responsible Opioid Prescribing: A Physician's Guide. Washington, DC: Waterford Life Sciences; 2007.
29. Drug Enforcement Administration, Office of Diversion Control. Questions & answers: state prescription monitoring programs. http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm. Updated July 2010. Accessed October 13, 2010.
30. White AG, Birnbaum HG, Schiller M, Tang J, Katz N. Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care. 2009;15(12):897-906.
31. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clinic Proc. 2009;84(7):593-601.
32. Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.